These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 24722796

  • 1. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH, Xu XL, Ruan HH, Xu WZ, Li D, Feng JG, Han QB, Mao WM.
    Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
    [Abstract] [Full Text] [Related]

  • 2. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D.
    Int J Cancer; 2014 Dec 01; 135(11):2687-96. PubMed ID: 24729390
    [Abstract] [Full Text] [Related]

  • 3. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.
    Clin Lung Cancer; 2013 Jul 01; 14(4):433-9. PubMed ID: 23522953
    [Abstract] [Full Text] [Related]

  • 4. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL, Hu LM, Huang MD, Zhao W, Yin YM, Hu ZB, Ma HX, Shen HB, Shu YQ.
    Asian Pac J Cancer Prev; 2012 Jul 01; 13(3):851-6. PubMed ID: 22631660
    [Abstract] [Full Text] [Related]

  • 5. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.
    Peng J, Yang LX, Zhao XY, Gao ZQ, Yang J, Wu WT, Wang HJ, Wang JC, Qian J, Chen HY, Jin L, Bai CX, Han BH, Wang WM, Lu DR.
    Tumour Biol; 2013 Apr 01; 34(2):953-61. PubMed ID: 23412975
    [Abstract] [Full Text] [Related]

  • 6. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
    Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, Lin S, Zhang X, Tan W, Yu D, Nie S, Miao X, Lin D.
    J Thorac Oncol; 2011 Nov 01; 6(11):1793-800. PubMed ID: 21841506
    [Abstract] [Full Text] [Related]

  • 7. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.
    Asian Pac J Cancer Prev; 2012 Nov 01; 13(5):2157-62. PubMed ID: 22901187
    [Abstract] [Full Text] [Related]

  • 8. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH.
    Asian Pac J Cancer Prev; 2009 Nov 01; 10(5):859-64. PubMed ID: 20104979
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH, Deng J, Shi DH, Ouyang XN, Niu PG.
    Clin Transl Oncol; 2015 Sep 01; 17(9):720-6. PubMed ID: 26033426
    [Abstract] [Full Text] [Related]

  • 10. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH, Yin JY, Liu ZQ.
    Chin J Cancer; 2016 Sep 02; 35(1):85. PubMed ID: 27590272
    [Abstract] [Full Text] [Related]

  • 11. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D, Xu W, Zhang ZW, Qian J, Zheng H, Zhang J, Su B.
    Asian Pac J Cancer Prev; 2015 Sep 02; 16(2):775-81. PubMed ID: 25684524
    [Abstract] [Full Text] [Related]

  • 12. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B, Guo Z, Ma Y, Kang S, Wang Y, Wei Q, Wu X.
    Int J Clin Exp Pathol; 2015 Sep 02; 8(4):4113-9. PubMed ID: 26097600
    [Abstract] [Full Text] [Related]

  • 13. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.
    Clin Lung Cancer; 2009 Mar 02; 10(2):118-23. PubMed ID: 19362955
    [Abstract] [Full Text] [Related]

  • 14. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.
    Clin Lung Cancer; 2017 Mar 02; 18(2):178-188.e4. PubMed ID: 27908619
    [Abstract] [Full Text] [Related]

  • 15. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, Song X, Wang J, Jin L, Wu J, Li Q, Bai C, Han B, Gao Z, Lu D.
    Tumour Biol; 2014 Nov 02; 35(11):11159-70. PubMed ID: 25104092
    [Abstract] [Full Text] [Related]

  • 16. Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy.
    Singh A, Singh N, Behera D, Sharma S.
    Pathol Oncol Res; 2019 Oct 02; 25(4):1327-1340. PubMed ID: 29209987
    [Abstract] [Full Text] [Related]

  • 17. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.
    Tan X, Wu Q, Cai Y, Zhao X, Wang S, Gao Z, Yang Y, Li X, Qian J, Wang J, Su B, Chen H, Han B, Jiang G, Lu D.
    Clin Lung Cancer; 2014 Jan 02; 15(1):67-78.e12. PubMed ID: 24220096
    [Abstract] [Full Text] [Related]

  • 18. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R, Krawczyk P, Homa-Mlak I, Powrózek T, Ciesielka M, Kozioł P, Milanowski J, Małecka-Massalska T.
    Pathol Oncol Res; 2019 Jul 02; 25(3):1035-1045. PubMed ID: 30066234
    [Abstract] [Full Text] [Related]

  • 19. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
    Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.
    Lung Cancer; 2012 Jan 02; 75(1):102-9. PubMed ID: 21676483
    [Abstract] [Full Text] [Related]

  • 20. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
    Zou ZQ, Du YY, Sui G, Xu SN.
    Asian Pac J Cancer Prev; 2015 Jan 02; 16(8):3189-94. PubMed ID: 25921119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.